Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC)

Historical Holders from Q1 2014 to Q2 2025

Symbol
RVNC
Type / Class
Equity / Common Stock, par value $0.001 per share
Shares outstanding
104,661,494
All holders as of 30 Jun 2025
Q2 2025
Total 13F shares, excl. options
0
Holdings value
$0
Number of holders
0
Number of sells
-2
Average sells %
-0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Teoxane SA 6.2% 0% $32,335,404 6,550,800 0% Teoxane SA 30 Jan 2025
FRANKLIN RESOURCES INC 4.6% $23,617,550 4,784,658 Franklin Resources, Inc. 30 Sep 2024
Palo Alto Investors LP 1.54% $7,955,942 1,611,787 Patrick Lee, MD 30 Sep 2024

Institutional Holders of Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q2 0 $0 -$425,556 0
2025 Q1 86,100 $425,000 -$246,196,147 $4.94 1
2024 Q4 81,619,644 $248,123,678 -$34,475,559 $3.04 169
2024 Q3 82,760,696 $429,420,057 +$74,534,872 $5.19 197
2024 Q2 81,357,406 $209,091,543 -$16,845,100 $2.57 167
2024 Q1 83,208,743 $409,387,692 +$36,028,524 $4.92 182
2023 Q4 72,393,492 $636,347,111 -$60,448,695 $8.79 188
2023 Q3 77,847,333 $892,932,350 -$137,486,235 $11.47 184
2023 Q2 81,758,941 $2,069,347,401 +$120,257,967 $25.31 211
2023 Q1 76,516,583 $2,464,233,089 +$117,647,825 $32.21 215
2022 Q4 73,838,140 $1,363,055,604 +$97,419,982 $18.46 189
2022 Q3 67,635,567 $1,824,203,436 +$329,402,349 $27 178
2022 Q2 56,025,691 $774,315,063 +$10,576,060 $13.82 156
2022 Q1 54,547,989 $1,063,491,136 +$29,861,073 $19.5 149
2021 Q4 52,976,629 $864,638,987 -$84,608,748 $16.32 143
2021 Q3 54,870,424 $1,528,696,909 +$20,536,734 $27.86 155
2021 Q2 54,097,996 $1,601,222,557 -$17,874,204 $29.64 159
2021 Q1 54,835,912 $1,532,629,456 +$56,326,804 $27.95 148
2020 Q4 52,750,406 $1,494,882,254 +$97,410,291 $28.34 150
2020 Q3 49,472,050 $1,246,067,821 -$26,647,818 $25.14 151
2020 Q2 50,606,433 $1,234,538,861 +$33,125,299 $24.42 138
2020 Q1 49,442,358 $731,960,359 -$26,411,053 $14.8 126
2019 Q4 51,033,735 $828,265,787 +$132,605,351 $16.23 130
2019 Q3 42,640,327 $554,389,602 -$12,035,697 $13 106
2019 Q2 43,555,026 $564,029,588 +$26,762,019 $12.97 110
2019 Q1 41,642,925 $656,297,834 +$99,780,800 $15.76 108
2018 Q4 31,877,280 $641,628,318 +$12,346,028 $20.13 97
2018 Q3 34,359,383 $853,830,934 -$15,526,982 $24.85 108
2018 Q2 34,870,390 $957,229,930 +$13,863,223 $27.45 109
2018 Q1 34,209,499 $1,053,625,660 -$35,231,819 $30.8 118
2017 Q4 34,965,934 $1,250,026,502 +$169,498,952 $35.75 115
2017 Q3 27,433,692 $754,721,335 -$1,638,080 $27.55 84
2017 Q2 27,519,844 $726,508,386 +$33,694,307 $26.4 84
2017 Q1 26,264,507 $546,296,202 +$45,342,975 $20.8 76
2016 Q4 26,097,588 $540,211,722 +$12,064,735 $20.7 80
2016 Q3 28,646,674 $464,359,406 -$1,083,385 $16.21 74
2016 Q2 28,779,485 $391,398,386 +$16,844,693 $13.6 79
2016 Q1 27,202,736 $474,936,380 -$25,989,904 $17.46 83
2015 Q4 27,209,685 $929,575,673 +$189,567,566 $34.16 101
2015 Q3 21,644,614 $644,108,702 +$34,896,748 $29.76 76
2015 Q2 20,482,234 $655,028,876 +$16,033,415 $31.98 88
2015 Q1 20,573,529 $426,461,171 +$18,511,994 $20.73 70
2014 Q4 19,758,262 $334,697,612 +$8,318,779 $16.94 68
2014 Q3 15,656,921 $302,653,761 -$45,140,381 $19.33 80
2014 Q2 16,360,522 $556,147,916 +$154,810,773 $34 98
2014 Q1 11,832,924 $372,736,175 +$372,736,179 $31.5 65